Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh

Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...